injectable glp-1 agonists America's Poison Centers Non-insulin injectable antidiabetic drugs -

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

Satiety regulation (reduces appetite, aiding in weight loss)

Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption

Personalized diet and exercise interventions, alongside pharmacological treatments, are crucial for enhancing both metabolic and psychological outcomes, ensuring a more sustainable and effective approach to managing obesity

See how GLP-1s are reshaping diabetes & obesity care.

Whats keeping the pills from taking off?